National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes. Insulin degludec (Tresiba?) is a new basal ultra-long-acting insulin analogue with a flat, stable gl...
Enregistré dans:
Auteur principal: | Gagik Radikovich Galstyan |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/24b4ef9c9f704b85892f4bf526c0a719 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
par: Lyudmila Alexandrovna Suplotova, et autres
Publié: (2015) -
Insulin degludec is a new ultra-long-acting insulin analogue
par: Ivan Ivanovich Dedov, et autres
Publié: (2014) -
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
par: M. V. Shestakova, et autres
Publié: (2021) -
Modern basal insulins: an ongoing story or the start of a new era?
par: Ivan Ivanovich Dedov
Publié: (2015) -
Fear of hypoglycaemia in patients with type 1 diabetes
par: Evgenia Mikhailovna Patrakeeva, et autres
Publié: (2014)